Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
DUMC Ped. CRS
mi
from
Durham, NC
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
DUMC Ped. CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Philadelphia IMPAACT Unit CRS
mi
from
Philadelphia, PA
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Philadelphia IMPAACT Unit CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Children's Medical Center of Dallas
mi
from
Dallas, TX
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Texas Children's Hosp. CRS
mi
from
Houston, TX
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Texas Children's Hosp. CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Children's Hosp. of the King's Daughters, Infectious Disease
mi
from
Norfolk, VA
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Children's Hosp. of the King's Daughters, Infectious Disease
mi
from
Norfolk, VA
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated:  3/7/2016
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds.
mi
from
Bayamon,
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents
Status: Enrolling
Updated: 3/7/2016
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds.
mi
from
Bayamon,
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Univ. of Colorado Denver NICHD CRS (5052)
mi
from
Aurora, CO
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Univ. of Colorado Denver NICHD CRS (5052)
mi
from
Aurora, CO
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Univ. of Miami Ped. Perinatal HIV/AIDS CRS (4201)
mi
from
Miami, FL
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Univ. of Miami Ped. Perinatal HIV/AIDS CRS (4201)
mi
from
Miami, FL
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
University of South Florida Tampa (5018)
mi
from
Tampa, FL
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
University of South Florida Tampa (5018)
mi
from
Tampa, FL
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Chicago Children's CRS (4001)
mi
from
Chicago, IL
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Chicago Children's CRS (4001)
mi
from
Chicago, IL
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Tulane University (5095)
mi
from
New Orleans, LA
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Tulane University (5095)
mi
from
New Orleans, LA
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Boston Medical Center Ped. HIV Program NICHD CRS (5011)
mi
from
Boston, MA
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Boston Medical Center Ped. HIV Program NICHD CRS (5011)
mi
from
Boston, MA
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Bronx-Lebanon Hospital IMPAACT CRS (6901)
mi
from
Bronx, NY
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Bronx-Lebanon Hospital IMPAACT CRS (6901)
mi
from
Bronx, NY
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Metropolitan Hospital (5003)
mi
from
New York, NY
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Metropolitan Hospital (5003)
mi
from
New York, NY
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
New York University NY (5012)
mi
from
New York, NY
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
New York University NY (5012)
mi
from
New York, NY
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
St. Jude/UTHSC CRS (6501)
mi
from
Memphis, TN
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
St. Jude/UTHSC CRS (6501)
mi
from
Memphis, TN
Click here to add this to my saved trials
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated:  3/8/2016
Texas Children's Hosp. CRS (3801)
mi
from
Houston, TX
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents
Status: Enrolling
Updated: 3/8/2016
Texas Children's Hosp. CRS (3801)
mi
from
Houston, TX
Click here to add this to my saved trials
Effect of Antacids on the Pharmacokinetics of Raltegravir
Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers
Status: Enrolling
Updated:  3/8/2016
University of Colorado Denver
mi
from
Aurora, CO
Effect of Antacids on the Pharmacokinetics of Raltegravir
Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers
Status: Enrolling
Updated: 3/8/2016
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated:  3/8/2016
City of Long Beach Department of Health and Human Services
mi
from
Long Beach, CA
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated: 3/8/2016
City of Long Beach Department of Health and Human Services
mi
from
Long Beach, CA
Click here to add this to my saved trials
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated:  3/8/2016
University of Southern California
mi
from
Los Angeles, CA
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated: 3/8/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated:  3/8/2016
Harbor UCLA Medical Center
mi
from
Torrance, CA
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated: 3/8/2016
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated:  3/8/2016
University of California, San Diego
mi
from
San Diego, CA
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Status: Enrolling
Updated: 3/8/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
City of Long Beach Department of Health and Human Services
mi
from
Long Beach, CA
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
City of Long Beach Department of Health and Human Services
mi
from
Long Beach, CA
Click here to add this to my saved trials
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
University of Southern California
mi
from
Los Angeles, CA
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
University of California, San Diego
mi
from
San Diego, CA
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
University of Southern California
mi
from
Los Angeles, CA
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
Harbor UCLA Medical Center
mi
from
Torrance, CA
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated:  3/8/2016
University of California, San Diego
mi
from
San Diego, CA
CCTG 594: Engagement and Retention in Care for HIV+
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Status: Enrolling
Updated: 3/8/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Genetics and HIV-1 Protease Inhibitors
Genetic-determinants of Protease Inhibitor Pharmacology
Status: Enrolling
Updated:  3/8/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Genetics and HIV-1 Protease Inhibitors
Genetic-determinants of Protease Inhibitor Pharmacology
Status: Enrolling
Updated: 3/8/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
University Hospital At University of Alabama, Birmingham (Uab)
mi
from
Birmingham, AL
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
University Hospital At University of Alabama, Birmingham (Uab)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Jackson Memorial Hospital
mi
from
Miami, FL
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Jackson Memorial Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
University of Miami
mi
from
Miami, FL
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Grady Memorial Hospital
mi
from
Atlanta, GA
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Stroger Cook County Hospital/Rush University Medical Center
mi
from
Chicago, IL
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Stroger Cook County Hospital/Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Hahnemann University Hospital
mi
from
Philadelphia, PA
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Parkland Health and Human Services
mi
from
Dallas, TX
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Parkland Health and Human Services
mi
from
Dallas, TX
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Los Angeles County Harbor-UCLA Medical Center
mi
from
Torrance, CA
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Los Angeles County Harbor-UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated:  3/10/2016
Boston Med Ctr
mi
from
Boston, MA
Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Status: Enrolling
Updated: 3/10/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
Status: Enrolling
Updated:  3/11/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
Status: Enrolling
Updated: 3/11/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated:  3/11/2016
AHF Research Center
mi
from
Beverly Hills, CA
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated: 3/11/2016
AHF Research Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated:  3/11/2016
Anthony Mills MD Inc
mi
from
Los Angeles, CA
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated: 3/11/2016
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated:  3/11/2016
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated: 3/11/2016
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated:  3/11/2016
Orange Coast Medical Group
mi
from
Newport Beach, CA
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status: Enrolling
Updated: 3/11/2016
Orange Coast Medical Group
mi
from
Newport Beach, CA
Click here to add this to my saved trials